Positive Medicines Board Opinion, Stock Price Updates, Drug Approval, Dividend Announcement, and Settlement of Claims - Analyst Notes on Allergan, Amgen, Teva, Lilly and Medtronic

NEW YORK, May 9, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Eli Lilly and Co. (NYSE: LLY) and Medtronic Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2265-100free.

Allergan Inc. Analyst Notes
On May 1, 2014, Allergan Inc. (Allergan) announced that its BOTOX® has received a positive opinion from the Irish Medicines Board serving as reference member state in the mutual recognition procedure (MRP) for the treatment of focal spasticity of the ankle in adult post stroke patients. According to the Company, this will facilitate as an important step in securing national licences in the 14 European countries involved in the MRP and marks a key milestone in bringing this treatment to stroke survivors across Europe who are suffering from lower limb spasticity. The positive opinion of BOTOX is based on phase III, multi-centre, randomised, double-blind, placebo-controlled study, assessing the efficacy and safety of BOTOX® in patients with post-stroke lower limb spasticity affecting the ankle. The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/2265-AGN-09May2014.pdf

Amgen Inc. Analyst Notes
On May 6, 2014 Amgen Inc.'s (Amgen) stock declined 0.80% to end the trading session at $112.28, following the Nasdaq Composite that lost 1.38% over the same day. Amgen's stock opened the session at $112.56 and oscillated in the range of $112.20 - $113.67. A total of 3.76 million shares were traded during the day, which was below its 30-day average volume of 4.49 million shares. The stock has a 52-week high of $128.96 and a 52-week low of $94.15. Amgen's stock is now down by 5.88% compared with the closing of April 22, 2014, when the Company released its Q1 2014 financial results. Amgen's Q1 2014 adjusted diluted EPS came in at $1.87, missing 23 analysts' average estimate of $1.94 provided by Reuters. Over the past twelve months, the stock has returned 5.45%. The full analyst notes on Amgen are available to download free of charge at:

http://www.analystsreview.com/2265-AMGN-09May2014.pdf

Teva Pharmaceutical Industries Ltd. Analyst Notes
On May 5, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced that the U.S. Food and Drug Administration (FDA) has approved its SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for use. The Company informed that with this approval physicians who treat adults with chronic or accelerated phase CML who are no longer responding to, or who could not tolerate, two or more tyrosine kinase inhibitors (TKIs) will now have the option to allow their patients to administer SYNRIBO® therapy at home. The Company is currently engaged in finalizing a comprehensive specialty pharmacy support program which will help facilitate successful home administration of SYNRIBO® for HCPs, their patients and caregivers. The Company expects this program to be available in Q2 2014. The full analyst notes on Teva are available to download free of charge at:

http://www.analystsreview.com/2265-TEVA-09May2014.pdf

Eli Lilly and Co. Analyst Notes
On May 5, 2014, Eli Lilly and Co. (Lilly) announced that the Company's Board of Directors has declared Q2 2014 dividend of $0.49 per share on outstanding common stock, payable on June 10, 2014 to shareholders of record at the close of business on May 15, 2014. The full analyst notes on Lilly are available to download free of charge at:

http://www.analystsreview.com/2265-LLY-09May2014.pdf

Medtronic Inc. Analyst Notes
On May 6, 2014, Medtronic Inc. (Medtronic) announced that the Company has entered into an agreement with certain plaintiffs' counsel to settle their inventories of filed and unfiled product liability claims related to INFUSE® Bone Graft. According to the terms of the agreement, the Company will resolve claims of approximately 950 claimants for a total payment of approximately $22 million. The Company expects to take a special charge in the range of $120 - $140 million in its recently completed Q4 2013 under the guidelines of FAS 5. Medtronic stated that this charge represents an estimated $22 million settlement cost of approximately 3,800 additional claims, and certain costs associated with these settlements. The full analyst notes on Medtronic are available to download free of charge at:

http://www.analystsreview.com/2265-MDT-09May2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review